WO2001068074A3 - Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds - Google Patents

Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds Download PDF

Info

Publication number
WO2001068074A3
WO2001068074A3 PCT/US2001/006884 US0106884W WO0168074A3 WO 2001068074 A3 WO2001068074 A3 WO 2001068074A3 US 0106884 W US0106884 W US 0106884W WO 0168074 A3 WO0168074 A3 WO 0168074A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugated
methods
estrogenic compounds
mixture
mixtures containing
Prior art date
Application number
PCT/US2001/006884
Other languages
French (fr)
Other versions
WO2001068074A2 (en
Inventor
Edward N Hill
Thomas W Leonard
Frederick D Sancilio
Katherin M Schlipp
Dean G Shirazi
Robert R Whittle
Original Assignee
Endeavor Pharmaceuticals
Edward N Hill
Thomas W Leonard
Frederick D Sancilio
Katherin M Schlipp
Dean G Shirazi
Robert R Whittle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endeavor Pharmaceuticals, Edward N Hill, Thomas W Leonard, Frederick D Sancilio, Katherin M Schlipp, Dean G Shirazi, Robert R Whittle filed Critical Endeavor Pharmaceuticals
Priority to JP2001566638A priority Critical patent/JP2004500396A/en
Priority to EP01918326A priority patent/EP1267852A2/en
Priority to MXPA02008856A priority patent/MXPA02008856A/en
Priority to AU4541701A priority patent/AU4541701A/en
Priority to CA002402559A priority patent/CA2402559A1/en
Priority to AU2001245417A priority patent/AU2001245417B2/en
Publication of WO2001068074A2 publication Critical patent/WO2001068074A2/en
Publication of WO2001068074A3 publication Critical patent/WO2001068074A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

A composition of matter is provided having a mixture of active estrogenic compounds. The mixture is present in chemically pure form. The mixture includes salts of conjugated estrone, conjugated equilin, conjugated Δ8,9-dehydroestrone, conjugated 17α-estradiol, conjugated 17α-dihydroequilin, conjugated 17α-dihydroequilin, conjugated 17β-estradiol, conjugated equilenin, conjugated 17α-dihydroequilenin, and conjugated 17β-dihydroequilenin. The mixture also contains the same essential estrogenic compounds present in naturally derived equine conjugated estrogens. Drug products including the composition of matter are also provided, as are methods of using these drug products to treat mammals in need of treatment. Methods of analyzing mixtures containing conjugated estrogens are also provided.
PCT/US2001/006884 2000-03-10 2001-03-05 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds WO2001068074A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001566638A JP2004500396A (en) 2000-03-10 2001-03-05 Pharmaceutical compositions of conjugated estrogens and methods for analyzing mixtures containing estrogen compounds
EP01918326A EP1267852A2 (en) 2000-03-10 2001-03-05 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
MXPA02008856A MXPA02008856A (en) 2000-03-10 2001-03-05 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds.
AU4541701A AU4541701A (en) 2000-03-10 2001-03-05 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
CA002402559A CA2402559A1 (en) 2000-03-10 2001-03-05 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
AU2001245417A AU2001245417B2 (en) 2000-03-10 2001-03-05 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/524,132 US6855703B1 (en) 2000-03-10 2000-03-10 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US09/524,132 2000-03-10

Publications (2)

Publication Number Publication Date
WO2001068074A2 WO2001068074A2 (en) 2001-09-20
WO2001068074A3 true WO2001068074A3 (en) 2002-03-21

Family

ID=24087894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006884 WO2001068074A2 (en) 2000-03-10 2001-03-05 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds

Country Status (8)

Country Link
US (1) US6855703B1 (en)
EP (1) EP1267852A2 (en)
JP (2) JP2004500396A (en)
KR (2) KR100804224B1 (en)
AU (2) AU2001245417B2 (en)
CA (1) CA2402559A1 (en)
MX (1) MXPA02008856A (en)
WO (1) WO2001068074A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
SG153645A1 (en) * 2001-03-16 2009-07-29 Wyeth Corp Hormone replacement therapy
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US6977143B1 (en) * 2003-09-08 2005-12-20 Quest Diagnostics Investments Incorporated Determination of testosterone by mass spectrometry
KR101112537B1 (en) * 2004-06-03 2012-02-29 삼성전자주식회사 Liquid crystal display having multi domain and panel for the same
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
EP1853272A1 (en) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
AU2006330846A1 (en) * 2005-12-27 2007-07-05 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
BRPI0706925A2 (en) * 2006-01-20 2011-04-19 Pera Tree Pharmaceuticals Inc pharmaceutical composition for vaginal administration in a subject and method for treating urogenital symptoms of atrophic vaginitis
US20070287684A1 (en) * 2006-05-22 2007-12-13 Irshad Chaudry Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
US9693953B2 (en) * 2006-06-02 2017-07-04 Janet A. Chollet Method of treating atrophic vaginitis
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
US20100155594A1 (en) * 2008-12-23 2010-06-24 Goldman Mildred M Mass spectrometry assay for estrogenic compounds
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PL2782584T3 (en) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN105842379A (en) * 2016-06-02 2016-08-10 云南省农业科学院质量标准与检测技术研究所 Method for measuring phenolic estrogen by means of derivation
EP3272333A1 (en) * 2016-07-22 2018-01-24 Chemo Research, S.L. Vaginal composition comprising a combination of estrogen and vitamin d
CN109632982A (en) * 2018-12-05 2019-04-16 华南理工大学 A kind of method of quick measurement natural estrogen combination
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN114184712B (en) * 2021-12-27 2023-09-26 南通联亚药业股份有限公司 Method for detecting content of free steroid impurities in conjugated estrogens tablets
CN114088859B (en) * 2022-01-19 2022-04-08 北京金域医学检验实验室有限公司 Method for separating multi-component isomer and detecting 29 steroid hormones

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
EP0322020A1 (en) * 1987-12-22 1989-06-28 Akzo N.V. Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis
WO1996007416A1 (en) * 1994-09-09 1996-03-14 The Procter & Gamble Company Estrogens and parathyroid hormone for treating osteoporosis
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3230142A (en) 1963-03-25 1966-01-18 Upjohn Co Oral contraceptive compositions and methods
IL25265A (en) 1966-02-28 1969-12-31 Harnik M Estrane derivatives and their preparation
NL6615481A (en) 1966-11-02 1968-05-03
US3487152A (en) 1967-02-07 1969-12-30 Hoffmann La Roche Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances
DE1617837A1 (en) 1967-02-28 1971-04-08 Schering Ag Method of contraception
US3568828A (en) 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US3591688A (en) 1969-08-22 1971-07-06 American Home Prod Method of preventing ovulation and composition therefor
US3639600A (en) 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US3795734A (en) 1970-04-20 1974-03-05 American Home Prod Cyclic regimen of hormone administration for contraception
US3733407A (en) 1971-08-25 1973-05-15 Syntex Corp Menopause treatment
US3836651A (en) 1972-02-22 1974-09-17 Biolog Concepts Inc Novel oral contraceptive combination
DE2310963A1 (en) 1972-04-14 1974-09-05 Schering Ag METHOD OF CONTRACTION BY FOLLOWING STAGE COMBINATION PREPARATIONS
US3969502A (en) 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
US3932635A (en) 1972-04-24 1976-01-13 Syntex Corporation Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US3942641A (en) 1972-05-05 1976-03-09 Syntex Corporation Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
GB1399162A (en) 1972-06-29 1975-06-25 Schering Ag 6-keto-delta1,3,5-10-steroids and process for the manufacture of 6-keto-delta1,3,5-10-steroids
US4066757A (en) 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
DE2365103C3 (en) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Use of hormones for contraception
US4147783A (en) 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
DE2431694A1 (en) 1974-07-02 1976-03-04 Asche Ag Sequential, two-stage contraceptive agents - contg a gestagen in the first stage, a gestagen plus oestrogen in the second stage and opt complementary placeboss
NL7506407A (en) 1975-05-30 1976-12-02 Akzo Nv PROCESS FOR PREPARING AN ORAL ACTIVE PHARMACEUTICAL PREPARATION.
US4027019A (en) 1975-07-24 1977-05-31 Ortho Pharmaceutical Corporation 3-Oximes of D-17α-ethynyl-19-nortestosterone esters and method
US4145416A (en) 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
GB1561244A (en) 1977-03-18 1980-02-13 Laroche Navarron Sa Broparestrol based therapeutic compositions
US4291028A (en) 1977-12-30 1981-09-22 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4292315A (en) 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
DE2818164A1 (en) 1978-04-21 1979-10-31 Schering Ag 1,3-DIBENZOIC ACID ESTER OF 17ALPHA-ETHINYL-7 ALPHA -METHYL-1,3,5 (10) -OESTRATRIEN- 1,3,17 BETA -TRIOLS, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREOF
US4756907A (en) 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
NL8001593A (en) 1980-03-18 1981-10-16 Akzo Nv MULTI-PHASIC COMBINATION PREPARATION FOR ORAL ANTI-CONCEPTION.
US4383993A (en) 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
US4315925A (en) 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4425339A (en) 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4512986A (en) 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3341638A1 (en) 1983-11-17 1984-05-03 Hermann Dr.rer.nat. 8000 München Heßlinger Three-phase product for contraception composed of ethinylestradiol and lynestrenol
DE3347125A1 (en) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen MULTI-STAGE COMBINATION PREPARATION AND ITS USE FOR ORAL CONTRACTION
US5010070A (en) 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
DE3505433A1 (en) 1985-02-16 1986-08-21 Basf Ag, 6700 Ludwigshafen DIRECT TABLETING AIDS
DE3510555A1 (en) 1985-03-21 1986-09-25 Schering AG, 1000 Berlin und 4709 Bergkamen ESTRIOLESTER
US4816257A (en) 1985-09-20 1989-03-28 Research & Education Institute, Harbor-Ucla Medical Center Inc. Method for producing an in vivo environment suitable for human embryo transfer
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5208225A (en) 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US4762717A (en) 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4855305A (en) 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
EP0300523B1 (en) 1987-07-06 1991-08-14 Akzo N.V. Pharmaceutical dosage unit for the prevention or treatment of climacteric complaints
US4900734A (en) 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US5108995A (en) 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5276022A (en) 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
DE3741801A1 (en) 1987-12-07 1989-06-15 Schering Ag 17-Methylene-estratrienes
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
NL8801670A (en) 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan PHARMACEUTICAL PREPARATION.
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
US5200197A (en) 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5098714A (en) 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
DE4104385C1 (en) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
HU222501B1 (en) 1991-06-28 2003-07-28 Endorecherche Inc. Controlled release pharmaceutical composition containing mpa or mga and process for its preparation
ZA924811B (en) 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters
IL107343A (en) 1992-11-02 2003-10-31 Wyeth Corp PHARMACEUTICAL COMPOSITION FOR LOWERING BLOOD LIPID LEVEL, COMPRISING, 17alpha-DIHYDROEQUILENIN
SG52359A1 (en) * 1993-01-05 1998-09-28 American Home Prod Anti-atherosclerotic agents
US5547948A (en) 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5759577A (en) 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5861431A (en) 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5807586A (en) 1996-07-30 1998-09-15 Energetics, Inc. Method of dietary supplementation
US6040333A (en) 1996-07-30 2000-03-21 Energetics, Inc. Dietary supplements
US5654011A (en) 1996-07-30 1997-08-05 Energetics, Inc. Dietary supplements
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
EP0322020A1 (en) * 1987-12-22 1989-06-28 Akzo N.V. Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis
WO1996007416A1 (en) * 1994-09-09 1996-03-14 The Procter & Gamble Company Estrogens and parathyroid hormone for treating osteoporosis
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5908638A (en) * 1995-07-26 1999-06-01 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
POOLE S K ET AL: "Separation of pharmaceutically important estrogens by micellar electrokinetic chromatography", JOURNAL OF CHROMATOGRAPHY A, ELSEVIER SCIENCE, NL, vol. 749, no. 1-2, 18 October 1996 (1996-10-18), pages 247 - 255, XP004069810, ISSN: 0021-9673 *
VAN DER WAL S., HUBER J.F.K.: "comparative study of several phase systems for the separation of estrogen conjugates by high-pressure liquid chromatography.", JOURNAL OF CHROMATOGRAPHY, vol. 149, 1978, pages 431 - 453, XP001033751 *

Also Published As

Publication number Publication date
JP2011256181A (en) 2011-12-22
JP2004500396A (en) 2004-01-08
AU2001245417B2 (en) 2005-10-06
AU4541701A (en) 2001-09-24
KR20070045364A (en) 2007-05-02
KR20030064614A (en) 2003-08-02
WO2001068074A2 (en) 2001-09-20
CA2402559A1 (en) 2001-09-20
KR100804224B1 (en) 2008-02-18
EP1267852A2 (en) 2003-01-02
US6855703B1 (en) 2005-02-15
MXPA02008856A (en) 2004-10-14

Similar Documents

Publication Publication Date Title
WO2001068074A3 (en) Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
CA2609336C (en) Quadraphasic continuous graduated estrogen contraceptive
HK1054332A1 (en) Novel topical oestroprogestational compositions with systemic effect
RS20060348A (en) Extended use combination comprising estrogens and progestins
HUP0104718A3 (en) Micronized eplerenone compositions, process for their preparation and use thereof for the preparation of pharmaceutical compositions
CA2542854C (en) Graduated estrogen contraceptive
HK1084015A1 (en) Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2-
HUP0302093A3 (en) Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
ATE307591T1 (en) PREPARATIONS CONTAINING A STEROID HORMONE AND A STABILIZING AGENT IN NON-CRYSTALLINE FORM
CA2431645A1 (en) Methods of treating hormonal deficiencies in women undergoing estrogen replacement therapy
KR970706001A (en) PROCESS OF MAKING DOSAGE UNITS BY WET GRANULATION BY WET-GRANULATION
JP4716726B2 (en) New etonogestrel ester
RU2001101892A (en) TESTOSTERONE DERIVATIVE
HUP0200173A2 (en) Combined use of estrogen and progestogen, norethindrone acetate and ethinyl estradiol for preparing pharmaceutical compositions for preventing and treating skin aging and acne
AP1625A (en) Hormonal composition based on a progesterone and an oestrogen and use thereof.
RU2003107072A (en) APPLICATION OF THE HORMONAL COMPOSITION CONTAINING A COMBINATION OF ESTROGEN AND PROGESTAGEN
BR9712274A (en) Hormonal composition consisting of an estrogen compound and a progestational compound
JP2003514861A5 (en)
ES2171110A1 (en) Pharmaceutical composition based on ibuprofen and a procedure for the preparation thereof
CR6627A (en) NEW CONTRACEPTIVE MEDICINAL PRODUCT AND ITS PREPARATION MODE
KR970704473A (en) DOSAGE STEROID TABLETS CONTAINING GALLIC ACID ESTERS AS ANTIOXIDANT AGENT, PROCESS FOR THE MANUFACTURE OF SAID TABLETS, AND USES OF SAID TABLETS). The present invention relates to low-dosage steroid tablets containing a gallic acid ester as an antioxidant,
RU1789216C (en) Composition showing contraceptive effect
WO2000067708A3 (en) Oral steroidal hormone compositions and methods of use
DE50109175D1 (en) 4-HALOGENATED 17-METHYLENE STEROIDS, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001245417

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 566638

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008856

Country of ref document: MX

Ref document number: 2402559

Country of ref document: CA

Ref document number: 1020027011837

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001918326

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001918326

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027011837

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2001245417

Country of ref document: AU